Home/Pipeline/Antibody Therapeutics (Bacterial Targets)

Antibody Therapeutics (Bacterial Targets)

Antibiotic-Resistant Bacterial Infections

Pre-clinicalActive Discovery & Engineering

Key Facts

Indication
Antibiotic-Resistant Bacterial Infections
Phase
Pre-clinical
Status
Active Discovery & Engineering
Company

About AbVacc

AbVacc is a private biotechnology company leveraging advanced protein engineering and immunology to create novel vaccines and antibody therapeutics against infectious diseases. Operating since 2008 in the BioCapital region of Maryland, the company's platform is designed to address the significant health and economic threats posed by emerging viral and bacterial targets, as highlighted by the COVID-19 pandemic. Their approach combines intelligent immunogen design with sophisticated antibody discovery to develop broad-spectrum protective solutions. The company brings together expertise in vaccinology, virology, bacteriology, and product development to advance its pipeline.

View full company profile

Therapeutic Areas